title: Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent.
abstract: Me-lex, a methyl sulfonate ester appended to a neutral N-methylpyrrolecarboxamide-based dipeptide, was synthesized to preferentially generate N3-methyladenine (3-MeA) adducts which are expected to be cytotoxic rather than mutagenic DNA lesions. In the present study, the sequence specificity for DNA alkylation by Me-lex was determined in the p53 cDNA through the conversion of the adducted sites into single strand breaks and sequencing gel analysis. In order to establish the mutagenic and lethal properties of Me-lex lesions, a yeast expression vector harboring the human wild-type p53 cDNA was treated in vitro with Me-lex, and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter. The results showed that: 1) more than 99% of the lesions induced by Me-lex are 3-MeA; 2) the co-addition of distamycin quantitatively inhibited methylation at all minor groove sites; 3) Me-lex selectively methylated A's that are in, or immediately adjacent to, the lex equilibrium binding sites; 4) all but 6 of the 33 independent mutations were base pair substitutions, the majority of which (17/33; 52%) were AT-targeted; 5) AT --> TA transversions were the predominant mutations observed (13/33; 39%); 6) 13 out of 33 (39%) independent mutations involved a single lex-binding site encompassing positions A600-602 and 9 occurred at position 602 which is a real Me-lex mutation hotspot (n = 9, p < 10(-6), Poisson's normal distribution). A hypothetical model for the interpretation of mutational events at this site is proposed. The present work is the first report on mutational properties of Me-lex. Our results suggest that 3-MeA is not only a cytotoxic but also a premutagenic lesion which exerts this unexpected property in a strict sequence-dependent manner.
authors.affiliation: Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Nebraska 69198-6805, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Kelly
authors.forename: A
authors.initials: A
authors.lastname: Inga
authors.forename: F X
authors.initials: FX
authors.lastname: Chen
authors.forename: P
authors.initials: P
authors.lastname: Dande
authors.forename: D
authors.initials: D
authors.lastname: Shah
authors.forename: P
authors.initials: P
authors.lastname: Monti
authors.forename: A
authors.initials: A
authors.lastname: Aprile
authors.forename: P A
authors.initials: PA
authors.lastname: Burns
authors.forename: G
authors.initials: G
authors.lastname: Scott
authors.forename: A
authors.initials: A
authors.lastname: Abbondandolo
authors.forename: B
authors.initials: B
authors.lastname: Gold
authors.forename: G
authors.initials: G
authors.lastname: Fronza
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000378:metabolism; D000477:Alkylating Agents / Q000378:metabolism; D000478:Alkylation; D001483:Base Sequence; D019175:DNA Methylation; D004252:DNA Mutational Analysis; D006801:Humans; D008969:Molecular Sequence Data; D009429:Netropsin / Q000031:analogs & derivatives* / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D000477:Alkylating Agents; D016159:Tumor Suppressor Protein p53; C110963:methyl lexitropsin; C025946:3-methyladenine; D009429:Netropsin; D000225:Adenine